CXCL10 and systemic lupus erythematosus: The RhoA/ROCK inhibitor in turn reduced type I IFN-induced STAT-1 phosphorylation and ISRE reporter gene expression, as well as OAS1 and CXCL10 in human lupus PBMCs.